Navigation Links
Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
Date:11/6/2008

rward- looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.

HALOZYME THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - UNAUDITED

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2008 AND 2007

Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007

REVENUES:

Revenue under

collaborative

agreements $2,194,325 $757,629 $5,209,897 $1,920,192

Product sales 267,901 185,252 492,066 541,420

Total Revenues 2,462,226 942,881 5,701,963 2,461,612

OPERATING EXPENSES:

Cost of product

sales 130,720 59,454 205,036 211,200

Research and

development 10,080,775 6,352,397 27,450,454 13,265,645

Selling, general

and administrative 3,450,450 2,840,683 11,454,228 7,207,544

Total Operating

Expenses 13,661,945 9,252,534 39,109,718 20,684,389

LOSS FROM OPERATIONS (11,199,719) (8,309,653) (33,407,755) (18,222,777)

Interest income 327,561 1,280,871 1,579,210 3,034,985

NET LOSS $(10,872,158) $(7,028,782) $(31,828,545) $(15,187,792)

Basic and diluted

net loss per share $(0.14) $(0.09) $(0.40) $(0.21)

Shares used in

computing net loss

per share,

basic and diluted 80,293,800 76,502,867 79,383,614 73,259,130

<
'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
2. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
3. Halozyme Therapeutics to Present at Upcoming Investor Conferences
4. Halozyme Therapeutics to Host Research Day for Investors and Analysts
5. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
6. Halozyme Therapeutics to Present at Upcoming Investor Conferences
7. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
8. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
9. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
10. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
11. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... TeselaGen Biotechnology has received ... expand their bioCAD/CAM software suite, which uses synthetic ... Small Business Innovation Research Phase II grant will be ... license from the Lawrence Berkeley National Laboratory. j5 was ... LBNL laboratory that develops alternative fuel technologies for the ...
(Date:10/1/2014)... -- Industry leaders from retail pharmacies ... the theme, ,Commercial Opportunities in the Era of Reform, ... Elsevier , a world-leading provider of scientific, technical ... gathering of some of the industry,s most prominent healthcare ... and in the future. The Elsevier Healthcare ...
(Date:9/30/2014)... . , Electrical ... a new kind of building block for digital integrated ... be based on three-dimensional arrangements of nanometer-scale magnets instead ... semiconductor industry CMOS fabrication of silicon chips ... the University of Notre Dame are exploring "magnetic computing" ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... and segments with highest potential revenues Do you ... updated report gives you revenue predictions for those ... For those therapies you find financial data, R&D ... analysis you get sales forecasts to 2024 at ...
Breaking Biology Technology:TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5
... June 27 the U.S. Supreme Court decided Metro-Goldwyn-Mayer ... decision affects how software companies and other technology providers ... be used to play, transmit or store copyrighted content. ... favor of MGM, reversing a lower court decision favoring ...
... seek to protect and enhance the value of the ... the business' products and services. Each year, several hundred ... them for federal trademark registration. Indeed, applications for trademark ... indicator of economic conditions (a steep drop in federal ...
... change in how things are done inside a corporation cannot ... is a difficult thing to pin down and even harder ... behaviors of an organization. , ,When culture drives positive ... distinct leg up on the competition. Just ask anybody working ...
Cached Biology Technology:Tech vendors could be liable for customer behavior - and not just file sharing 2Tech vendors could be liable for customer behavior - and not just file sharing 3Why file for trademark protection? 2Why file for trademark protection? 3Why file for trademark protection? 4Why corporate culture counts 2Why corporate culture counts 3Why corporate culture counts 4
(Date:9/30/2014)... the Ocean Health Index rates the Earth,s oceans ... In addition, for the first time, the report ... beyond national jurisdiction (high-seas areas) all critical ... and providing sustainable food sources. , In the ... led by scientists from UC Santa Barbara,s National ...
(Date:9/30/2014)... the popular attention of both children and aquarium hobbyists ... as dehydrated eggs, these tiny brine shrimp readily hatch, ... of salt water. , Physicists, though, are interested ... vertically migrate in large groups in response to changing ... and retreating deeper during the day. , Two researchers ...
(Date:9/30/2014)... a Salk professor and Howard Hughes Medical Institute ... been named recipients in the 2014 round of ... through the BRAIN (Brain Research through Advancing Innovative ... grant, announced September 30, provides more than $3 ... three years. , The BRAIN Initiative, launched last ...
Breaking Biology News(10 mins):Rating the planet's oceans 2Rating the planet's oceans 3Laser-guided sea monkeys show how zooplankton migrations may affect global ocean currents 2Salk scientists receive $3 million for BRAIN Initiative grant 2
... Scientists of the Institute of Tropical Medicine (ITG) discovered a ... medicine, but at the same time had become better in ... helped in developing a superbug. For it appears the battle ... host. "To our knowledge it is the first time such ...
... examining the prevalence of the fungus Fusarium ... be a common source of human infections. In the ... State,s College of Agricultural Sciences sampled nearly 500 sink ... and public facilities -- in Pennsylvania, Maryland, Virginia, North ...
... their use as biotechnology power horses, Trichoderma ... in the field are brought together and highlighted in ... on 27 December. Trichoderma are free-living ... Trichoderma are specifically used as biocontrol agents ...
Cached Biology News:Do our medicines boost pathogens? 2Do our medicines boost pathogens? 3Disease-causing strains of Fusarium prevalent in plumbing drains 2Disease-causing strains of Fusarium prevalent in plumbing drains 3Exploiting Trichoderma: From food security to biotechnology 2
Dopamine D2 and D3 receptor, human and possibly mouse. AB1502 detects 40 ng of dopamine receptor peptide by ELISA. AB1502 is not neutralizing....
Anti-MMP-7, aminoterminal end active enzyme; rabbit host...
Request Info...
Rabbit polyclonal to Phosphothreonine-Proline / Phosphoserine-Proline ( Abpromise for all tested applications)....
Biology Products: